Impact of Infectious Diseases on Product Procurement and Logistics
First written in FY2022. 1 of 4 entries say "Materialised", first in FY2022. Latest entry: FY2023.
1 other company's latest entry also says "Reframed".
- FY2023ReframedAnnual report
「If an abnormal situation exceeding the company's expectations occurs, such as a pandemic at one of the company's facilities or at a business partner,」
COVID-19 is no longer described as a separate risk, and pandemics, including infectious diseases, are included within natural disaster and abnormal event risks. - FY2023-Q3MitigatedAnnual report
「During the cumulative period of the first 3 quarters, restrictions on activities introduced in response to COVID-19 were eased and economic activity began to normalize. As a result, domestic consumption showed signs of recovery in spending on services and a return to physical stores.」
The company describes the easing of activity restrictions and the normalization of economic activity, stating that the impact of infectious diseases on consumption and business activity has eased from the previous fiscal year. However, uncertainty about consumption trends remains. - FY2023-Q2RestatedAnnual report
「During the cumulative period of the first 2 quarters, Japan experienced the seventh wave of the domestic COVID-19 outbreak, in addition to」
The company identifies the continued spread of infectious diseases as a factor contributing to uncertainty in the business environment. It states that there have been no material changes in business and other risks. - FY2022MaterialisedAnnual report
「As the effects of COVID-19 continue for an extended period, uncertainty about the outlook remains due to global logistics disruptions and the impact of foreign exchange rates, among other factors.」
Although production and transportation of products have been affected by the spread of infectious diseases overseas, the company states that the current impact is limited by obtaining information from business partners and adjusting the timing of product launches.